ELVIS JACOME: Open Payments
NPI 1720138365 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,923 in 144 payments from 23 companies in 2025. Trend: 2023 $1,617 · 2024 $2,634 · 2025 $2,923
Food & beverage: $2,772Education: $150
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 24 | $439 |
| VERTEX PHARMACEUTICALS INCORPORATED | 11 | $274 |
| Lilly USA, LLC | 9 | $253 |
| Janssen Biotech, Inc. | 12 | $249 |
| Novartis Pharmaceuticals Corporation | 14 | $248 |
| Galderma Laboratories, L.P. | 13 | $240 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $228 |
| Arcutis Biotherapeutics, Inc. | 11 | $182 |
| UCB, Inc. | 8 | $166 |
| Regeneron Healthcare Solutions, Inc. | 5 | $160 |
Products named: OPZELURA, JOURNAVX, TREMFYA, NEMLUVIO, Zoryve, DUPIXENT, ILUMYA, Bimzelx.
Industry payments across TX — which companies pay providers there.
